77 related articles for article (PubMed ID: 11251384)
1. DNA-encoding enzymatically active HIV-1 reverse transcriptase, but not the inactive mutant, confers resistance to experimental HIV-1 challenge.
Isaguliants MG; Petrakova NN; Zuber B; Pokrovskaya K; Gizatullin R; Kostyuk DA; Kjerrström A; Winberg G; Kochetkov SN; Hinkula J; Wahren B
Intervirology; 2000; 43(4-6):288-93. PubMed ID: 11251384
[TBL] [Abstract][Full Text] [Related]
2. A truncated plasmid-encoded HIV-1 reverse transcriptase displays strong immunogenicity.
Hallengärd D; Wahren B; Bråve A
Viral Immunol; 2013 Apr; 26(2):163-6. PubMed ID: 23573980
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 reverse transcriptase artificially targeted for proteasomal degradation induces a mixed Th1/Th2-type immune response.
Starodubova ES; Boberg A; Litvina M; Morozov A; Petrakova NV; Timofeev A; Latyshev O; Tunitskaya V; Wahren B; Isaguliants MG; Karpov VL
Vaccine; 2008 Sep; 26(40):5170-6. PubMed ID: 18468738
[TBL] [Abstract][Full Text] [Related]
4. Immunogenic properties of reverse transcriptase of HIV type 1 assessed by DNA and protein immunization of rabbits.
Isaguliants MG; Gudima SO; Ivanova OV; Levi M; Hinkula J; Garaev MM; Kochetkov SN; Wahren B
AIDS Res Hum Retroviruses; 2000 Sep; 16(13):1269-80. PubMed ID: 10957724
[TBL] [Abstract][Full Text] [Related]
5. Oxidative stress induced by HIV-1 reverse transcriptase modulates the enzyme's performance in gene immunization.
Isaguliants M; Smirnova O; Ivanov AV; Kilpelainen A; Kuzmenko Y; Petkov S; Latanova A; Krotova O; Engström G; Karpov V; Kochetkov S; Wahren B; Starodubova E
Hum Vaccin Immunother; 2013 Oct; 9(10):2111-9. PubMed ID: 23881028
[TBL] [Abstract][Full Text] [Related]
6. Potent cross-reactive immune response against the wild-type and drug-resistant forms of HIV reverse transcriptase after the chimeric gene immunization.
Starodubova E; Boberg A; Ivanov A; Latyshev O; Petrakova N; Kuzmenko Y; Litvina M; Chernousov A; Kochetkov S; Karpov V; Wahren B; Isaguliants MG
Vaccine; 2010 Feb; 28(8):1975-86. PubMed ID: 20188253
[TBL] [Abstract][Full Text] [Related]
7. Reverse transcriptase-based DNA vaccines against drug-resistant HIV-1 tested in a mouse model.
Isaguliants MG; Zuber B; Boberg A; Sjöstrand D; Belikov SV; Rollman E; Zuber AK; Rechinsky VO; Rytting AS; Källander CF; Hinkula J; Kochetkov SN; Liu M; Wahren B
Vaccine; 2004 Apr; 22(13-14):1810-9. PubMed ID: 15068865
[TBL] [Abstract][Full Text] [Related]
8. Fusion to Flaviviral Leader Peptide Targets HIV-1 Reverse Transcriptase for Secretion and Reduces Its Enzymatic Activity and Ability to Induce Oxidative Stress but Has No Major Effects on Its Immunogenic Performance in DNA-Immunized Mice.
Latanova A; Petkov S; Kuzmenko Y; Kilpeläinen A; Ivanov A; Smirnova O; Krotova O; Korolev S; Hinkula J; Karpov V; Isaguliants M; Starodubova E
J Immunol Res; 2017; 2017():7407136. PubMed ID: 28717654
[TBL] [Abstract][Full Text] [Related]
9. Codon optimization and improved delivery/immunization regimen enhance the immune response against wild-type and drug-resistant HIV-1 reverse transcriptase, preserving its Th2-polarity.
Latanova AA; Petkov S; Kilpelainen A; Jansons J; Latyshev OE; Kuzmenko YV; Hinkula J; Abakumov MA; Valuev-Elliston VT; Gomelsky M; Karpov VL; Chiodi F; Wahren B; Logunov DY; Starodubova ES; Isaguliants MG
Sci Rep; 2018 May; 8(1):8078. PubMed ID: 29799015
[TBL] [Abstract][Full Text] [Related]
10. A novel potent strategy for induction of immunity to HIV-1 reverse transcriptase in primates.
Zuber B; Mäkitalo B; Zuber AK; Wahren B
AIDS; 2002 Sep; 16(13):1839-40. PubMed ID: 12218401
[No Abstract] [Full Text] [Related]
11. Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model.
Rollman E; Mathy N; Bråve A; Boberg A; Kjerrström A; van Wely C; Engström G; Johansson S; Aperia K; Eriksson LE; Benthin R; Ertl P; Heeney J; Hinkula J; Voss G; Wahren B
Vaccine; 2007 Mar; 25(11):2145-54. PubMed ID: 17254672
[TBL] [Abstract][Full Text] [Related]
12. Intranasal immunization with HIV reverse transcriptase: effect of dose in the induction of helper T cell type 1 and 2 immunity.
Pacheco SE; Gibbs RA; Ansari-Lari A; Rogers P
AIDS Res Hum Retroviruses; 2000 Dec; 16(18):2009-17. PubMed ID: 11153084
[TBL] [Abstract][Full Text] [Related]
13. Introducing a frameshift mutation to the POL sequence of HIV-1 provirus and evaluation of the immunogenic characteristics of the mutated virions (RINNL4-3).
Zabihollahi R; Sadat SM; Vahabpour R; Salehi M; Azadmanesh K; Siadat SD; Saraji AR; Pouriavali MH; Momen SB; Aghasadeghi MR
Mol Biol (Mosk); 2012; 46(3):519-24. PubMed ID: 22888641
[TBL] [Abstract][Full Text] [Related]
14. Improvement in T helper 1-related immune responses in BALB/c mice immunized with an HIV-1 gag plasmid combined with a chimeric plasmid encoding interleukin-18 and flagellin.
Chen YL; Chen YS; Hung YC; Liu PJ; Tasi HY; Ni WF; Hseuh PT; Lin HH
Microbiol Immunol; 2015 Aug; 59(8):483-94. PubMed ID: 26094825
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 DNA vaccine efficacy is enhanced by coadministration with plasmid encoding IFN-alpha.
Jiang W; Ren L; Jin N
J Virol Methods; 2007 Dec; 146(1-2):266-73. PubMed ID: 17868910
[TBL] [Abstract][Full Text] [Related]
16. Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques.
Smith JM; Amara RR; McClure HM; Patel M; Sharma S; Yi H; Chennareddi L; Herndon JG; Butera ST; Heneine W; Ellenberger DL; Parekh B; Earl PL; Wyatt LS; Moss B; Robinson HL
AIDS Res Hum Retroviruses; 2004 Jun; 20(6):654-65. PubMed ID: 15242543
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of epitope-specific cellular immune responses by immunization with HIV-1 peptides genetically conjugated to the B-subunit of recombinant cholera toxin.
Boberg A; Gaunitz S; Bråve A; Wahren B; Carlin N
Vaccine; 2008 Sep; 26(40):5079-82. PubMed ID: 18514370
[TBL] [Abstract][Full Text] [Related]
18. Cross-clade protection induced by human immunodeficiency virus-1 DNA immunogens expressing consensus sequences of multiple genes and epitopes from subtypes A, B, C, and FGH.
Malm M; Rollman E; Ustav M; Hinkula J; Krohn K; Wahren B; Blazevic V
Viral Immunol; 2005; 18(4):678-88. PubMed ID: 16359234
[TBL] [Abstract][Full Text] [Related]
19. Candidate HIV-1 gp140DeltaV2, Gag and Tat vaccines protect against experimental HIV-1/MuLV challenge.
Bråve A; Hinkula J; Cafaro A; Eriksson LE; Srivastava IK; Magnani M; Ensoli B; Barnett SW; Wahren B; Rollman E
Vaccine; 2007 Sep; 25(39-40):6882-90. PubMed ID: 17707956
[TBL] [Abstract][Full Text] [Related]
20. The rationale behind a vaccine based on multiple HIV antigens.
Rollman E; Bråve A; Boberg A; Gudmundsdotter L; Engström G; Isaguliants M; Ljungberg K; Lundgren B; Blomberg P; Hinkula J; Hejdeman B; Sandström E; Liu M; Wahren B
Microbes Infect; 2005 Nov; 7(14):1414-23. PubMed ID: 16257558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
